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IMPORTANCE Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasmwith
distinctive pathologic, molecular, and clinical features as well as the potential to respond to
new targeted drugs. Little is known on the activity of anthracycline-based regimens,
gemcitabine-based regimens, and pazopanib in this disease.
OBJECTIVE To report on the activity of anthracycline-based regimens, gemcitabine-based
regimens, and pazopanib in patients with advanced ES.
DESIGN, SETTING, AND PARTICIPANTS Seventeen sarcoma reference centers in Europe, the
United States, and Japan contributed data to this retrospective analysis of patients with
locally advanced/metastatic ES diagnosed between 1990 and 2016. Local pathological review
was performed in all cases to confirm diagnosis according to most recent criteria.
EXPOSURES All patients included in the study received anthracycline-based regimens,
gemcitabine-based regimens, or pazopanib.
MAIN OUTCOME ANDMEASURES Responsewas assessed by RECIST. Progression-free survival
(PFS) and overall survival (OS) were computed by Kaplan-Meier method. Classic and proximal
subtypes were defined based onmorphology (according to 2013World Health Organization
guidelines).
RESULTS Overall, 115 patients were included, 80 (70%) weremen and 35 (30%) were
women, with a median age of 32 years (range, 15-77 years). Of the 115 patients with ES, 85
were treated with anthracycline-based regimens, 41 with gemcitabine-based regimens, and
18 with pazopanib. Twenty-four receivedmore than 1 treatment. Median follow-up was 34
months. Response rate for anthracycline-based regimens was 22%, with a median PFS of 6
months. One complete response (CR) was reported. A trend toward a higher response rate
was noticed in morphological proximal type (26%) vs classic type (19%) and in proximal vs
distal primary site (26% vs 18%). The response rate for gemcitabine-based regimens was
27%, with 2 CR and amedian PFS of 4months. In this group, a trend toward a higher
response rate was reported in classic vs proximal morphological type (30% vs 22%) and in
distal vs proximal primary site (40% vs 14%). In the pazopanib group, no objective responses
were seen, andmedian PFS was 3months.
CONCLUSIONS AND RELEVANCE This is the largest retrospective series of systemic therapy in
ES. We confirm amoderate activity of anthracycline-based and gemcitabine-based regimens
in ES, with a similar response rate and PFS in both groups. The value of pazopanib was low.
These data may serve as a benchmark for trials of novel agents in ES.
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E pithelioid sarcoma (ES) is a rare sarcoma subtype,withan incidence rate of 0.02 per 100000 and 0.05 per100000 inEurope and theUnitedStates, respectively.1
World Health Organization classification distinguishes
2 morphological variants of ES: the classic type and the
proximal type, both predominantly integrase interactor 1
(INI1) deficient.2-4
Theprognosis inES is serious, especially forproximal type,
with a 5-year overall survival (OS) rate of 50%.1 In metastatic
patients, the reported median survival is approximately
12 months.5-9
The current knowledge on the activity of commonly used
drugs for sarcoma in ES is based on limited retrospective
studies.8,10-13 This is particularly relevant today, when new
target agents potentially active in this disease are under
evaluation.14
The aim of this international, collaborative study, includ-
ing 17 referral sarcoma centers in Europe, the United States,
and Japan participating in the World Sarcoma Network ef-
fort, was to report on the activity of anthracycline-based
regimens, gemcitabine-based regimens, and pazopanib in
adult patients with advanced ES.
Methods
Population
We considered all patients with locally advanced/metastatic
ES, diagnosed between January 1990 and June 2016, treated
with anthracycline-based, gemcitabine-based regimens, or
pazopanib. Patients treated with adjuvant/neoadjuvant in-
tentwereexcluded.Approvalby the institutional reviewboard
of each institution was obtained, and written informed con-
sent was obtained as required by local regulation.
Study Design
Datawereextracted fromclinicaldatabases.Thediagnosis and
morphological subtypewere reviewedandconfirmedbyeach
institutional sarcoma pathologist. Treatment response was
assessed according to RECIST 1.1.15
Statistical Analyses
Descriptive statisticswereused tosummarizepopulationchar-
acteristics. Comparisons between response rates were made
using Fisher exact tests.
Progression-free survival (PFS) andOSwere estimatedby
usingKaplan-Meiermethod,distributionsbygroupwere com-
paredthrough log-ranktests.Progression-freesurvivalwascal-
culated from the treatment start to the first documented evi-
dence of progressive disease (PD), death owing to any cause,
or last follow-up. Patients undergoing surgery after medical
treatments were censored at the time of PD after surgical re-
section or at the last follow-up. Overall survival was calcu-
lated from the treatment start to the time of death from any
cause or the last follow-up. A 2-sided P < .05 was considered
statistically significant. Statistical analyses were carried out
with SAS (version 9.4, SAS Institute Inc) andR statistical soft-
ware (version 3.4.0, R Foundation).
Results
Population
One-hundred-fifteen patients with locally advanced/
metastatic ES treated with an anthracycline-based regimen,
gemcitabine-based regimen, or pazopanib were identified.
Among them, 80 (70%) weremen and 35 (30%) were women.
The median age in the population was 32 years (range, 15-77
years). The median follow-up was 34 months (interquartile
range [IQR], 22-210 months). The median OS was 17.8 (IQR,
9.5-33.1)months. Integrase interactor1wasdeficient inallevalu-
able cases. The Table summarizes patient characteristics.
Treatment Response andOutcome
Eighty-five, 41, and 18 patients were included in the anthra-
cycline group, gemcitabine group, and pazopanib group,
respectively. Twenty-four patients received more than 1 of
the selected treatments. eTables 1 and 2 in the Supplement
report treatment details.
Anthracycline-Based Regimens
Best RECIST response for anthracycline-based regimens was
1 complete response (CR, 1%), 18 (21%) partial response (PR),
45 (53%) stable disease (SD), and 21 (25%) PD. The response
rate was 22%.
The median PFS was 6 (IQR, 2.3-10.4) months. The me-
dian PFS in responding patients was 9 months (IQR, 4.6-
20.6), 7 in proximal type (IQR, 3-21), and 9 in classic type ES
(IQR, 7-not evaluable [NE]). The median PFS in nonrespond-
ing patients was 5 months (IQR, 2.2-9.2), 4 in proximal type
(IQR, 2-9), and 5 in classic type ES (IQR, 3-10). ThemedianOS
(all lines of therapy considered together)was 16months (IQR,
8.4-28.6).
Gemcitabine-Based Regimens
Best RECIST response for gemcitabine-based regimens was
2 (5%) CR, 9 (22%) PR, 16 (39%) SD, and 14 (34%) PD. The
response rate was 27%.
The median PFS was 4 (IQR, 2.0-11.9) months. The me-
dian PFS in responding patients was 16months (IQR, 7.1-NE),
20 inproximal type (IQR, 13-NE), and 10 inclassic typeES (IQR,
Key Points
Question Are anthracycline-based regimens, gemcitabine-based
regimens,andpazopanibactive inadvancedepithelioidsarcoma(ES)?
Finding Thismulti-institutional caseseries included115patientswith
advancedES treatedwith anthracycline-based regimens (85),
gemcitabine-basedregimens(41),orpazopanib(18)between1990and
2016 at 17 sarcoma centers in Europe, theUnited States, and Japan.
Theresponserateandthemedianprogression-freesurvival (PFS) inthe
anthracycline-groupwere 22%and6months; 27%and4months in
the gemcitabine-group;0 and3monthswith pazopanib.
Meaning Anthracycline-based and gemcitabine-based regimens
are moderately active in advanced ES, with similar response rates
and PFS, whereas the activity of pazopanib seemed limited.
Research Brief Report Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma
E2 JAMAOncology Published online April 12, 2018 (Reprinted) jamaoncology.com
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a IRCCS Istituto Nazionale Tumori, Milano User  on 04/13/2018
7-NE). The median PFS in nonresponding patients was 3
months (IQR, 1.7-6.2), 3 inbothproximal typeandclassic type.
The median OS was 19 months (IQR, 8.9-37.3).
Pazopanib
Best RECIST response with pazopanib was 9 (50%) SD and 9
(50%)PD.TwoprolongedSDwereobserved(27and21months).
The median PFS and OS were 3 (IQR, 2.1-11.2) and 14 (IQR,
5-33.1) months, respectively.
eTable 3 in the Supplement reports response rate, me-
dian PFS, and median OS by subtype, primary site, and re-
sponse to treatment. eTable4 in theSupplement reportspopu-
lationoutcome.TheFigureshowsKaplan-Meiercurves forPFS.
Discussion
To our knowledge, this international retrospective study col-
lected the largest series currently availableofpatientswithad-
vanced ES treated with systemic therapy. One hundred fif-
teen patients were included. Anthracycline-based regimens
(response rate, 22%) and gemcitabine-based regimens (re-
sponse rate, 27%) are active in a proportion of patients with
ES. A trend toward a higher response rate to anthracycline-
based regimenswasnoticed inpathologic proximal type com-
pared with classic type ES, and in patients with anatomically
proximal tumor sites.However, durationof responsewas low,
particularly in proximal type ES. In the gemcitabine-based
treatment group, the response rate was slightly higher in pa-
tients with morphological classic type ES and distal primary
sites.No responseswere seenwithpazopanibandPFSwas low.
Given the rarity of ES, collaborative retrospective efforts
are of major relevance to provide clinical guidance. With all
the limitations of a retrospective study, our case series is the
largest available on the activity of systemic therapies for pa-
tientswithES.Updated follow-upwas available formore than
90%ofpatients, thoughwith some limitations (since thedate
of last radiological assessment was unknown in some cases,
patientswerecensoredat the timeof the last follow-up).Patho-
logic diagnosis was confirmed by a dedicated sarcoma pa-
thologist and INI1 status was known in most cases.
In our series anthracycline-based regimens were associ-
atedwith an response rate of 22% and a 6-monthmedian PFS.
Of3publishedretrospectivestudies, resultsareconflictingabout
tumor response rate to anthracycline (ranging from 0 to 43%)
and PFS (3 to 8 months).8,10,13 In our series, we observed re-
sponses both in classic type (19%) and in proximal type (26%).
However, the median PFS in responding patients was low (9
months), particularly for proximal type ES. Our data might
therefore encourage the use of anthracyclines in the proximal
type, especially if some integration with surgery is foreseen.
With gemcitabine-based regimens, we observed an re-
sponse rate of 27% and amedian PFS of 4months, confirming
whatwaspreviouslyreportedbyPinketal10 (responserate,58%;
PFS, 8 months). The responses observed by Pink and col-
leagues were similar in both subtypes, whereas in our study
gemcitabine-based regimens appeared slightly more active in
classic type ES (30% vs 22%) and distal primary site. A favor-
able PFS was observed in responding patients of both sub-
types, especially in the proximal type subgroup. In distal type
ES the natural history of diseasemay be a confounding factor.
The activity of pazopanib in our studywas limited. Nota-
bly, pazopanib was mainly used in further line and in a lim-
ited number of patients. A long-lasting PR in a proximal type
ES (INI1undetermined) treated in first-linehasbeenreported.11
Although we cannot exclude the activity of pazopanib in
some cases, it seems inferior to anthracycline-based and
gemcitabine-based regimens.
Table. Population Characteristics
Characteristic
No. (%)
Anthracycline-based Gemcitabine-based Pazopanib
No. of patients 85 41 18
INI-1 IHC statusa
Deficient 59 (69) 31 (76) 17 (94)
Unavailable 26 (31) 10 (24) 1 (6)
Age, median (range), y 32 (15-77) 34 (15-76) 31 (15-67)
Sex
Male 61 (72) 26 (63) 13 (72)
Female 24 (28) 15 (37) 5 (28)
Primary siteb
Distal 34 (40) 20 (49) 10 (56)
Proximal 51 (60) 21 (51) 8 (44)
Histological type
Classic 43 (51) 23 (56) 11 (61)
Proximal 42 (49) 18 (44) 7 (39)
Stage
Locally advanced 14 (17) 1 (2) 3 (16.7)
Locoregional lymphnodal involvement 15 (18) 7 (17) 2 (11.1)
Metastatic 56 (66) 33 (81) 13 (72.2)
Abbreviations:
IHC, immunohistochemistry;
INI-1, integrase interactor 1.
a By immunohistochemical analysis.
bDistal primary sites: hand, forearm,
foot. Proximal primary sites: head,
neck, trunk, arm, axilla, thigh, groin,
buttock, urogenitalia.
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Conclusions
Although the number of patients was low, we observed
signs of a differential activity of anthracycline-based
and gemcitabine-based regimens between the 2 ES
variants. Unfortunately, we were not able to further break
down distal ES according to their more or less aggressive
morphologic appearance, in a disease regarded today as
high-grade by definition. Indeed, a degree of heterogeneity
can be observed upfront and across relapses. A further
subtype-adapted grading system based on pathologic
features and its correlation with treatment response would
be interesting to explore. We also hope that this report will
provide a benchmark for future trials on medical agents in
this disease.
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